How often IV B12 is given can vary from weekly to monthly, depending on how the patient responds and the reason for the deficiency
Most therapeutic protocols use 12-24 week cycles based on research protocols and individual goals
A 2009 study looking at dosing rats with oral BPC-157 found that the effectiveness of the peptide therapy was certainly present and that positive effectiveness was present
A 2003 study involving epithalamin (the substance from which synthetic epithalon is derived) found that epithalon has a positive effect on cardiovascular, endocrine, immune, and nervous systems, and may prolong the lifespan of elderly human test subjects [10]
Simultaneously, BPC-157 is shown acting directly on the brain to modulate neurotransmitters and promote neurogenesis, completing the therapeutic loop
A phase 3, openlabel GEMINI LTS study demonstrates vedolizumabs strong and favorable safety profile